Your browser doesn't support javascript.
loading
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Ferrante, Marc; Panaccione, Remo; Baert, Filip; Bossuyt, Peter; Colombel, Jean-Frederic; Danese, Silvio; Dubinsky, Marla; Feagan, Brian G; Hisamatsu, Tadakazu; Lim, Allen; Lindsay, James O; Loftus, Edward V; Panés, Julián; Peyrin-Biroulet, Laurent; Ran, Zhihua; Rubin, David T; Sandborn, William J; Schreiber, Stefan; Neimark, Ezequiel; Song, Alexandra; Kligys, Kristina; Pang, Yinuo; Pivorunas, Valerie; Berg, Sofie; Duan, W Rachel; Huang, Bidan; Kalabic, Jasmina; Liao, Xiaomei; Robinson, Anne; Wallace, Kori; D'Haens, Geert.
Affiliation
  • Ferrante M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium. Electronic address: marc.ferrante@uzleuven.be.
  • Panaccione R; Inflammatory Bowel Disease Unit and Gastrointestinal Research, University of Calgary, Calgary, AB, Canada.
  • Baert F; AZ Delta, Roeselare, Belgium.
  • Bossuyt P; Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium.
  • Colombel JF; Icahn School of Medicine at Mt Sinai, New York, NY, USA.
  • Danese S; Gastroenterology and Gastrointestinal Endoscopy Unit, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy.
  • Dubinsky M; Icahn School of Medicine at Mt Sinai, New York, NY, USA.
  • Feagan BG; Division of Gastroenterology, Department of Medicine, University of Western Ontario, London, ON, Canada.
  • Hisamatsu T; Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Kyorin University, Tokyo, Japan.
  • Lim A; University of Alberta, Edmonton, AB, Canada.
  • Lindsay JO; Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Loftus EV; Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
  • Panés J; Department of Gastroenterology, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
  • Peyrin-Biroulet L; Department of Gastroenterology, University of Lorraine, CHRU-Nancy, Nancy, France; Department of Gastroenterology, University of Lorraine, Inserm, NGERE, Nancy, France.
  • Ran Z; Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Inflammatory Bowel Disease Research Center, Shanghai, China; Renji Hospital School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Shanghai Institute of Digestive Disease,
  • Rubin DT; Section of Gastroenterology, Hepatology and Nutrition and Digestive Diseases Center, The University of Chicago Medicine, Chicago, IL, USA.
  • Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
  • Schreiber S; Department of General Internal Medicine, Christian-Albrechts-University, Kiel, Germany.
  • Neimark E; AbbVie, Chicago, IL, USA.
  • Song A; AbbVie, Chicago, IL, USA.
  • Kligys K; AbbVie, Chicago, IL, USA.
  • Pang Y; AbbVie, Chicago, IL, USA.
  • Pivorunas V; AbbVie, Chicago, IL, USA.
  • Berg S; AbbVie, Chicago, IL, USA.
  • Duan WR; AbbVie, Chicago, IL, USA.
  • Huang B; AbbVie, Chicago, IL, USA.
  • Kalabic J; AbbVie Deutschland, Ludwigshafen, Germany.
  • Liao X; AbbVie, Chicago, IL, USA.
  • Robinson A; AbbVie, Chicago, IL, USA.
  • Wallace K; AbbVie, Chicago, IL, USA.
  • D'Haens G; Inflammatory Bowel Disease Centre, Amsterdam University Medical Centre, Amsterdam, Netherlands.
Lancet ; 399(10340): 2031-2046, 2022 05 28.
Article in En | MEDLINE | ID: mdl-35644155
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Crohn Disease Type of study: Clinical_trials / Guideline Limits: Humans Language: En Journal: Lancet Year: 2022 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Crohn Disease Type of study: Clinical_trials / Guideline Limits: Humans Language: En Journal: Lancet Year: 2022 Type: Article